



# How can we better achieve integration of HCV, other co-infections and harm reduction services for PWID?

**19 Sept 2018, 16.15-17.30 (session G)**

Hotel Cascais Miragem,

Lisbon, Portugal

**Chair: Jeffrey Lazarus, Rigshospitalet, University of Copenhagen, CHIP (DK) and Jack Lambert, UCD/ Mater Misericordiae University Hospital (IE),**

People who inject drugs are at exceptionally high risk of contracting viral hepatitis as well as HIV and tuberculosis. In recognition of this, the European Union is supporting several projects including two Joint Actions on infectious diseases, one of which specifically focuses on people who inject drugs. This session will focus on integrating services and programmes in Europe for people who inject drugs, presenting new findings from major European projects. It provides an important opportunity for knowledge translation and professional development in this field.

## PROGRAMME

<b>16:15- 16:25</b>	<b>Opening session</b>  <b>Integration of HCV, other co-infections and harm reduction services for PWID in Portugal</b>  <b>João Castel-Branco Goulão (SICAD Diretor geral)</b>
<b>16:25- 16:35</b>	<b>How do EU agencies take an integrated approach to hepatitis C control?</b>  <b>Dagmar Hedrich, EMCDDA</b>
<b>16:35- 16:45</b>	<b>Best practice model from a Czech Republic prison</b>  <b>Viktor Mravčík, National Monitoring Centre for Drugs and Addiction (HA-REACT)</b>
	<b>Transitioning specialist HCV services into the community</b>
<b>16:45- 17:00</b>	<b>Hep-CARE EUROPE, John (Jack) Lambert, UCD/ Mater Misericordiae University Hospital (IE)</b>

Address  
Contact

Consumers, Health,  
Agriculture and Food  
Executive Agency

---

**17:00- 17:10 E-DETECT TB, Alistair Story, University College of London Hospital (UK)**

**17:10-17:30** Roundtable discussion :

- What does integration of services for PWID mean in terms of testing and providing treatment?
- How does the health systems need to change to better integrate and can it?
- Can we eliminate hepatitis C among PWID on opioid substitution therapy in the near future?

Panelists from:

Jeffrey Lazarus, Rigshospitalet, University of Copenhagen, CHIP (DK) and Viktor Mravčík, National Monitoring Centre for Drugs and Addiction (CZ), HA-REACT Joint Action.

John (Jack) Lambert, UCD/ Mater Misericordiae University Hospital (IE), HepCare EUROPE and INTEGRATE Joint Action

Alistair Story, University College Hospitals NHS Foundation Trust, London (UK), E-DETECT TB : Early detection and integrated management of tuberculosis in Europe, Find and Treat project, Title Chair/speaker

Raquel Duarte, Centro de Diagnóstico Pneumológico de Vila Nova de Gaia, Vila Nova Gaia (PT), Porto integrated care centre,

---